EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
platform
06-Oct-2025 / 14:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS
Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Ad hoc announcement
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
platform
Korneuburg, October 6, 2025 – Ad hoc announcement
Following the successful recent capital measures, the Management Board of
Marinomed Biotech AG, with the approval of the Supervisory Board, today
decided to begin reviewing strategic options for the Marinosolv platform.
Depending on the progress of the review, the evaluation process could
include strategic partnerships for the two projects Budesolv and
Tacrosolv, as well as the involvement of a strategist. Marinomed is
working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [1]pr@marinomed.com
E-Mail: [2]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed and Marinosolv® are registered trademarks of
Marinomed Biotech AG. These trademarks may be owned or licensed in select
locations only.
End of Inside Information
══════════════════════════════════════════════════════════════════════════
Information and Explanation of the Issuer to this announcement:
Ad hoc announcement
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv
platform
Korneuburg, October 6, 2025 – Ad hoc announcement
Following the successful recent capital measures, the Management Board of
Marinomed Biotech AG, with the approval of the Supervisory Board, today
decided to begin reviewing strategic options for the Marinosolv platform.
Depending on the progress of the review, the evaluation process could
include strategic partnerships for the two projects Budesolv and
Tacrosolv, as well as the involvement of a strategist. Marinomed is
working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [3]pr@marinomed.com
E-Mail: [4]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed and Marinosolv® are registered trademarks of
Marinomed Biotech AG. These trademarks may be owned or licensed in select
locations only.
══════════════════════════════════════════════════════════════════════════
06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2208704
End of Announcement EQS News Service
2208704 06-Oct-2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2208704&application_name=news&site_id=apa_ots_austria~~
References
Visible links
1. pr@marinomed.com
2. ir@marinomed.com
3. pr@marinomed.com
4. ir@marinomed.com
~
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender